Clinical Trial

Disease: Human Immunodeficiency Virus Infection, HIV (NCT05143307)

Disease info:

HIV stands for human immunodeficiency virus. It harms the immune system by destroying the white blood cells that fight infection, putting infected individuals at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS.

Frequency:
Worldwide, there were about 1.7 million new cases of HIV in 2018. About 37.9 million people were living with HIV around the world in 2018, and 23.3 million of them were receiving medicines to treat HIV, called antiretroviral therapy (ART).
Official title:
Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Study Where EBT-101 Was Administered
Who:

Excision BioTherapeutics

Sponsor:

Excision BioTherapeutics

Partners:

None

Locations:

United States, California

United States, Florida

United States, Missouri

United States, New Jersey

Study start:
Mar. 1, 2023
Enrollment:
9
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene disruption
Gene:
Undisclosed
Delivery method:
AAV9 - In-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status:

Description

Participants who receive EBT-101 in a treatment protocol as part of a Phase 1 trial for HIV will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002). All participants will have follow-up visits every six months until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually on the anniversary of EBT-101 administration until study completion at Year 15.

Last updated: Jan. 7, 2022
close
Search CRISPR Medicine